Enlivex Ltd
1BT
Company Profile
Business description
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.
Contact
14 Einstein Street
Weizmann Science Park
Ness Ziona7403618
ISRT: +972 86328500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
34
Stocks News & Analysis
stocks
Older cohorts the budget losers, not necessarily the ASX listed insurers
Proposed legislation removes health insurance rebates.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,717.00 | 82.40 | -0.94% |
| CAC 40 | 8,006.76 | 25.00 | 0.31% |
| DAX 40 | 24,444.41 | 43.76 | 0.18% |
| Dow JONES (US) | 49,363.88 | 322.24 | -0.65% |
| FTSE 100 | 10,320.59 | 9.96 | -0.10% |
| HKSE | 25,651.12 | 146.73 | -0.57% |
| NASDAQ | 25,870.71 | 220.02 | -0.84% |
| Nikkei 225 | 59,804.41 | 746.18 | -1.23% |
| NZX 50 Index | 12,761.03 | 213.29 | -1.64% |
| S&P 500 | 7,353.61 | 49.44 | -0.67% |
| S&P/ASX 200 | 8,496.60 | 76.50 | -0.89% |
| SSE Composite Index | 4,162.18 | 7.35 | -0.18% |